证券代码：688221 证券简称：前沿生物 公告编号：2025-006 重要内容提示： 公司将于 2025 年 4 月 30 日发布公司 2024 年年度报告以及 2025 年第一季度报告，为便于广大投资者更全面深入地了解公司 2024 年年 度以及 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 5 月 8 日 （星期四） 15:00-17:00 参加由上海证券交易所主办的 2024 年度科创板创新药行业集体业绩说明会并同时举行 2025 年第一季度业 绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 1 会议召开时间：2025 年 5 月 8 日 （星期四） 15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 5 月 7 日（星期三）16:00 前登录上证路演中心网站首 页点击"提问预征集"栏目或通过前沿生物药业（南京）股份有限 公司（以下简称"公司"）邮箱 invest@frontierbiotech. ...

前沿生物-U688221 时间: 2025年4月7日星期一 42.69分综合得分 偏弱 趋势方向 主力成本分析 7.78 元 当日主力成本 9.26 元 5日主力成本 9.47 元 20日主力成本 9.71 元 60日主力成本 周期内涨跌停 涨停 2次 跌停 0 次 技术面分析 9.80 过去一年内该股 短期压力位 9.30 短期支撑位 10.07 中期压力位 9.24 中期支撑位 股价跌破短期支撑位，短线观望为宜； 股价跌破中期支撑位，中期主力资金做多意愿不强，以观望为 宜 K线形态 ★跳空缺口★ 注意向上还是向下跳空，出现向上跳空缺口，并伴有较大的成交量时，可积极参与；若出现向下 跳空缺口，说明市况已发生逆转，原来的升势已经结束，继续下跌的可能性很大 资金流数据 | 主力资金净流出1320.62万元 | | --- | | 占总成交额-19% | | 超大单净流入0.00元 | | 大单净流出1320.62万元 | | 散户资金净流入192.55万 | 关联行业/概念板块 化学制药 -11.60%、病毒防治 -11.53%、创新药 -12.18%等 财务数据 最近的财报数据显示，该股于2025年04月07 ...

表型组数据具有量大、跨尺度和多维度等特点，在与遗传易感性、环境暴露及生活方式等传统疾病风险 因素整合分析时，面临数据质量不一、缺乏共享云平台及多维数据分析方法有限的问题。 当基因测序揭开生命的第一重密码，中国科学家正在向更深的维度进军：2025年3月24日，一项被业内 称为"破解生命密码"的国家重点研发计划项目——"前沿生物技术"重点专项"全基因组-环境/生活方式暴 露与跨尺度表型组大数据整合分析"正式启动。 该项目由福建医科大学副校长、公共卫生学院院长叶为民教授主持，医渡科技(02158)与复旦大学、西 湖大学、武汉大学、山东大学、中国科学院上海营养与健康研究所、中国医学科学院北京协和医院等10 家优势单位协同攻关，为心脑血管疾病、糖尿病、恶性肿瘤及慢性呼吸系统疾病四大慢病防治策略及措 施开发提供新思路。 作为核心参与单位，医渡科技主要承担疾病风险预测模型构建、多维表型组学数据整合分析系统建设等 关键任务。项目的启动不仅是我国在精准医学领域的又一关键落子，更是对慢性病防控发起的一场"科 研攻坚战"。 如果说人类基因组计划让科学家手里有了探索生命奥秘的"指南针（300803）"，那么人类表型组计划就 将打造未 ...

| 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- | --- | | 营业总收入 | 129, 472, 935, 98 | 114.249, 557. 31 | 13. 32 | | 营业利润 | -201, 227, 921. 69 | -327,732,439.68 | 不适用 | | 利润总额 | -201, 516, 971. 16 | -328, 964, 344. 09 | 不适用 | | 归属于母公司所有者的净利润 | -201.516.971.16 | -328,964,344.09 | 不适用 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | =336,186,335,47 | -354.596.018. 91 | 不适用 | 2023年，公司实现营业收入1.14亿元，同比增长34.82%；归母净利润为-3.29亿元，上年同期为-3.57 亿元；扣非净利润为-3.55亿元，上年同期为-3.99亿元；经营活动产生的现金流量净额为-2.67亿元，上 年同期为-2.89亿元。 2018年至2022年，公司营业收入分别为191.11万元 ...

艾可宁®作为前沿生物的核心产品，在2024年表现尤为突出。公司围绕该产品全面开展上市后研究与学 术推广活动，深度挖掘其临床优势，精准定位目标人群，并进一步拓展临床应用范围。门诊端，公司聚 焦高病载、抗病毒治疗未达标、免疫重建不全三类重点患者，提供个体化治疗方案；住院端，艾可宁® 凭借出色的治疗效果，促使更多住院患者在出院后选择基于艾可宁®的序贯治疗方案，显著提升了患者 的用药黏性和用药时长。 在市场拓展方面，前沿生物全力推进销售渠道下沉战略，将销售网络深度覆盖至县市级地区，优化药品 配送流程，显著提升了艾可宁®在基层市场的可及性。截至报告期末，艾可宁®已覆盖全国30个省及直 辖市的300余家HIV定点治疗医院及200余家DTP药房，并被29个省及直辖市纳入医保"双通道"及门慢门 特目录。 学术研究：艾可宁®研究成果获国际期刊收录 2月27日晚间，前沿生物(688221)发布2024年度业绩快报，公司2024年度实现营业总收入12947.29万元， 较上年同期增长13.32%，主要因为抗HIV创新药艾可宁®及多元化销售实现增长；亏损大幅收窄，较上 年同期减少亏损12744.74万元，显示出强劲的发展势头。 20 ...

Financial Performance - Total revenue for 2024 reached RMB 129.47 million, an increase of 13.32% compared to RMB 114.25 million in the previous year[4] - The net loss attributable to the parent company was RMB 201.52 million, a reduction in loss of RMB 12.74 million from RMB 328.96 million in the previous year[6] - Total assets at the end of the reporting period were RMB 1.81 billion, a decrease of 15.33% from RMB 2.14 billion at the beginning of the period[4] - The equity attributable to the parent company decreased by 15.01% to RMB 1.14 billion from RMB 1.34 billion at the beginning of the period[4] Research and Development - Research and development expenses for 2024 amounted to RMB 137.21 million, primarily focused on post-marketing studies of the innovative HIV drug Aikening®[6] - The company is advancing its pipeline projects, with a first-in-class small nucleic acid candidate drug entering the IND enabling stage[11] - The company aims to obtain approval for the FB4001 (teriparatide injection generic) by 2025 and is actively promoting its progress[11] Product Development and Market Expansion - Aikening® has been included in the medical insurance "dual channel" and outpatient special directory in 29 provinces and municipalities[8] - The company is actively expanding Aikening®'s market presence in outpatient and inpatient settings, focusing on high-burden patients[7] - Aikening® has shown significant clinical benefits in treating HIV-infected patients, with a successful case study published in the international journal BMC Pregnancy and Childbirth[9]

Financial Projections - The company expects to achieve an operating revenue of approximately CNY 125 million to CNY 130 million in 2024, representing a year-on-year increase of 9.41% to 13.79%[4] - The net loss attributable to shareholders is projected to be between CNY 182 million and CNY 220 million, a reduction in loss of approximately CNY 108.96 million to CNY 146.96 million compared to the previous year[4] - The company anticipates a net loss excluding non-recurring gains and losses of approximately CNY 315 million to CNY 354 million, a decrease in loss of about CNY 0.596 million to CNY 3.96 million[4] Research and Development - Research and development expenses are expected to be around CNY 134 million to CNY 139 million, a year-on-year decrease of 35.12% to 37.45%[8] - The company has received approval for a Phase II clinical trial for the new indication of its product Aikening® for "immune reconstitution in HIV-1 infected patients" from the National Medical Products Administration[12] - The company has submitted a generic drug marketing application for the FB3002 project (pain relief adhesive) to the National Medical Products Administration[13] Market Expansion and Partnerships - The company has expanded its coverage to over 300 HIV treatment hospitals and more than 200 DTP pharmacies across 30 provinces and municipalities in China[10] - The company has established a commercial partnership for the FB4001 project (teriparatide injection generic drug) in the U.S. market, aiming for commercialization by 2025[13] - The company continues to strengthen its market penetration and commercialization efforts for Aikening®, which has been included in the National Medical Insurance Directory for 2024[9] Financial Reporting - The financial data presented is preliminary and has not been audited by a registered accountant, with the final figures to be disclosed in the audited 2024 annual report[14]

Summary of Conference Call Records Company Overview - The company focuses on the development of innovative drugs in the field of chronic diseases, particularly in small nucleic acid therapies and high-end generic drugs, aiming to balance high investment and long R&D cycles associated with innovative drugs [1][2][3] Key Points Business Strategy and Development - The company has outlined a three-year development strategy focusing on: 1. Long-acting HIV therapies 2. Small nucleic acid drug development targeting chronic diseases 3. High-end generic drugs [1][2][3] - The company aims to maintain steady growth, with sales of its long-acting HIV product, Aikenin, projected to reach 1.09 billion in 2023 and approximately 780 million in the third quarter of 2024 [1][2][3] Product Pipeline - Aikenin is the first domestic long-acting HIV product, with sales expected to reach 3 to 4 billion GBP globally [3][4] - The company plans to submit Investigational New Drug (IND) applications for new products in 2025 and 2026, with additional submissions in 2027 [2][4] - The company is also developing a high-end generic drug, expected to launch in mid-2025, and another in 2026 [2][4] Market Dynamics - The global HIV market exceeds 40 billion, with over 39 million infections and 1.3 million new infections annually [8][9] - The domestic HIV patient base is over 1.32 million, with new infections ranging from 100,000 to 150,000 annually, primarily through sexual transmission [8][9] - The company anticipates growth in the domestic HIV market, paralleling trends observed in the U.S. market [8][9] Competitive Landscape - The company positions itself against established players like Gilead, which has a significant market presence with products exceeding 10 billion USD in sales [8][9] - The company aims to leverage its first-mover advantage in long-acting therapies to capture market share [3][4] Financial Health - The company has a strong cash flow, with total assets around 2.2 billion and net assets of approximately 1.15 billion as of the end of 2023 [3][4] - The company raised 1.8 billion through its IPO in 2020 and an additional 200 million in a follow-on offering in 2022 [3][4] Research and Development - The company has a robust R&D framework, focusing on long-acting therapies and small nucleic acid platforms, with ongoing projects targeting various chronic diseases [6][7][22][23] - The company has established partnerships for joint research, particularly in hepatitis B and HIV, to explore functional cures and new drug development [22][23] Regulatory and Market Access - The company has successfully navigated regulatory pathways, with Aikenin included in China's HIV treatment guidelines and covered by insurance since 2020 [14][18] - The company is expanding its market access through partnerships with hospitals and pharmacies, aiming to cover 80-90% of target patients [18][19] Future Outlook - The company is optimistic about the growth potential in the HIV market, with plans to expand its product offerings and enhance patient convenience through long-acting formulations [12][13][22] - The company is also exploring opportunities in the small nucleic acid space, with several projects in preclinical stages [22][23] Additional Insights - The company is addressing the growing need for convenient treatment options for HIV patients, focusing on long-acting injectable therapies that reduce the frequency of dosing [12][13] - The company is aware of the changing demographics of HIV patients, with increasing infections among older and younger populations, particularly among men who have sex with men [9][10]

证券代码：688221 证券简称：前沿生物 公告编号：2024-049 监事会 2024年12月28日 1 前沿生物药业（南京）股份有限公司 关于选举第四届监事会职工代表监事的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 前沿生物药业（南京）股份有限公司（以下简称"公司"）第三届监事会任 期已届满，根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规 则》和《公司章程》等有关规定，公司于 2024 年 12 月 27 日召开职工代表大会， 经出席会议的全体职工代表讨论、表决，同意选举姜志忠先生为公司第四届监事 会职工代表监事。姜志忠先生的简历详见附件。 公司第四届监事会由三名监事组成，包括两位非职工代表监事及一位职工代 表监事。姜志忠先生将与公司 2024 年第四次临时股东大会选举产生的两位非职 工代表监事共同组成第四届监事会，任期与第四届监事会任期一致。 特此公告。 前沿生物药业（南京）股份有限公司 附件： 姜志忠：男，1982 年出生，中国国籍，硕士研究生学历。曾任红太阳集团有限公 司研发中心研究员、采 ...

证券代码：688221 证券简称：前沿生物 公告编号：2024-048 前沿生物药业（南京）股份有限公司 关于第四届监事会第一次会议决议的公告 经与会监事审议表决，形成的会议决议如下： 1、 审议通过《关于选举公司第四届监事会主席的议案》 经审议，全体监事一致同意选举姜志忠先生为公司第四届监事会主席，任期 与第四届监事会任期一致。 具 体 内 容 详 见 公 司 同 日 披 露 于 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn/）的《关于完成董事会、监事会换届选举及聘任高级 管理人员、证券事务代表的公告》。 表决结果：3 票同意；0 票反对；0 票弃权。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 前沿生物药业（南京）股份有限公司（以下简称"公司"）第四届监事会第 一次会议通知于 2024 年 12 月 27 日以通讯方式送达全体监事。会议于 2024 年 12 月 27 日以现场结合通讯表决的方式召开。召集人已在监事会会议上就豁免监 事会会议通知的相关情况作 ...